Improving the Efficacy of Anti-Nicotine Immunotherapy

The purpose of this study is to find out how vaccine-induced antibodies change the way the
body processes nicotine from cigarettes. These antibodies absorb nicotine and can reduce
nicotine levels in the brain. In this way, the vaccination may help to quit smoking. The
central hypothesis is that anti-nicotine antibodies change kinetics of brain nicotine
accumulation and distribution of nicotine between the brain and other body tissues. This
vaccine is investigational which means that it is still being tested in research studies and
is not approved by the U.S. Food and Drug Administration (FDA) to help people quit smoking.